UBS Maintains Neutral on Calumet, Raises Price Target to $47
UBS analyst Manav Gupta maintains Calumet (NASDAQ:CLMT) with a Neutral and raises the price target from $26 to $47.
Read original at benzingaStocks · News reference
Calumet Specialty Prods Q2 EPS $(1.09) Misses $(0.34) Estimate, Sales $1.445B Beat $1.082B Estimate
Calumet Specialty Prods (NASDAQ:CLMT) reported quarterly losses of $(1.09) per share which missed the analyst consensus estimate of $(0.34) by 220.59 percent. This is a 35.88 percent increase over losses of $(1.70) per
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 7, 2026, 11:06 AM
- Checked
- Aug 7, 2026, 11:06 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Goldman Sachs Maintains Neutral on Calumet, Raises Price Target to $45
Goldman Sachs analyst Neil Mehta maintains Calumet (NASDAQ:CLMT) with a Neutral and raises the price target from $40 to $45.
Read original at benzingaTD Cowen Maintains Hold on Calumet, Raises Price Target to $40
TD Cowen analyst Jason Gabelman maintains Calumet (NASDAQ:CLMT) with a Hold and raises the price target from $34 to $40.
Read original at benzingaShares of oil and gas refining and marketing companies are trading higher amid energy price gains due to a possible impasse in U.S.-Iran negotiations, with Iran demanding war reparations and unfreezing of assets. Also, reports suggest President Trump is willing to end the war in exchange for reopening Hormuz without addressing Iran's nuclear program, which may lead to concerns over future military tensions.
Read original at benzinga